FDA approves Lilly's EBGLYSS for eight-week dosing in atopic dermatitis

June 9, 2026 6:19 PM

The U.S. Food and Drug Administration approved a new dosing regimen for Eli Lilly and Company's (NYSE: LLY) EBGLYSS (lebrikizumab-lbkz) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found